1 · Why one number on the label gets so much attention

When consumers first land on the LDV20 product page, one number usually stands out before everything else: Policosanol 20 mg. That is understandable. In a four-ingredient formula, the clearest signal is often the one that appears most prominently on the label, and in LDV20 the Policosanol amount functions as the anchor number that helps consumers immediately understand where the product sits within the Australian cardiovascular listed-medicine category.

This matters not only because it is the headline ingredient, but because the number itself is easy to compare across labels. A consumer may not instantly recognise botanical names such as Berberis aristata or Silybum marianum, but a clearly printed 20 mg figure is simple to notice, remember and verify. That is why the LDV20 formula begins with Policosanol on the front of the product story.

2 · What Policosanol 20 mg means on the LDV20 pack

On the official LDV20 materials, Pure Australia presents the product as featuring 20 mg of Policosanol per capsule. The same materials describe this as the maximum daily amount permitted in Australia for this ingredient within the listed-medicine framework, which gives the number practical meaning beyond simple marketing emphasis. It is not just an ingredient mention; it is a label-defining quantity.

In the public TGA ARTG entry for LDV20, the Policosanol source is recorded as sugar cane wax alcohols. That source detail matters because it connects the consumer-facing pack wording to the formal public register. In other words, the “Policosanol 20 mg” printed on the product page and the “sugar cane wax alcohols” listed on the ARTG entry are two parts of the same verification story.

3 · Why the Australian listed-medicine context matters

Numbers on supplement labels can mean very different things depending on the regulatory system behind them. In the Australian system, LDV20 is not presented as a general wellness food item; it is presented as an Australian Listed Medicine under AUST L 502251. That means the ingredient presentation sits inside a formal framework governed by the Therapeutic Goods Administration, with public registerability, sponsor accountability and manufacturing controls all attached to the product.

For consumers, that context matters because it turns the dose into a verifiable claim rather than just a front-label statement. The same product can be checked across three places: the label, the ARTG record, and the Official Information Center. When all three align, the 20 mg anchor gains credibility not only as a number, but as part of a transparent Australian product system.

4 · Where the 20 mg dose appears in the published literature

For consumers who like to look beyond the label, the 20 mg figure is also familiar from the published Policosanol literature. One of the best-known references is the Castaño G, et al. (2001) study comparing 20 mg/day with 40 mg/day in a double-blind design. This is one of the reasons the 20 mg dose is often discussed as a key practical reference point in the ingredient's history.

Another useful high-level source is the 2017 sugarcane-derived policosanol meta-analysis, which provides a broader look at how the ingredient has been represented across published studies. For a consumer reading LDV20 as a product rather than reading Policosanol as an isolated topic, these references help explain why the 20 mg quantity on the label feels familiar and substantial inside the category.

5 · Why LDV20 does not stop at Policosanol alone

Although Policosanol 20 mg is the anchor number, LDV20 is not designed as a one-ingredient story. Pure Australia presents LDV20 as a four-ingredient formula that combines the cardiovascular anchor of Policosanol with three complementary ingredients: Berberine, Milk Thistle, and Chromium. Each ingredient adds a different pathway context to the same once-daily routine.

This broader structure is one of the reasons LDV20 is easier to position as a daily wellness routine rather than only as a single-ingredient product. The Policosanol number draws initial attention, but the formula around it gives the product a fuller place in the consumer's day.

6 · How the 20 mg anchor fits into a once-daily routine

The once-daily routine described on the LDV20 product page is where the Policosanol anchor becomes practical rather than theoretical. A clear ingredient amount is useful, but it becomes much more meaningful when it is matched with a simple daily structure. That is exactly what LDV20 offers: one capsule, one main dose anchor, one easy-to-repeat rhythm.

From a consumer perspective, this simplicity is part of the product value. A product may contain well-known ingredients, but if the routine is awkward, the long-term experience becomes inconsistent. LDV20 avoids that problem by giving the 20 mg Policosanol anchor a routine that fits naturally into breakfast or another regular meal, while the 4 × 30 format described on the Official Information Center adds a visible monthly rhythm on top.

7 · How consumers can verify the dose and the listing

Because Pure Australia sells LDV20 directly into a transparency-focused category, the easiest way to build confidence is to show consumers how to verify the most important pack details for themselves. The 20 mg dose is one of those details.

1. Read the LDV20 product page and confirm the label wording around Policosanol 20 mg.
2. Open the public ARTG record for AUST L 502251 and confirm the ingredient source is listed as sugar cane wax alcohols.
3. Review the Official Information Center and the LDV20 FAQ for the same product facts in brand-side language.

When all three sources align, the consumer is not simply taking the brand's word for the dose. They are reading a product that is consistent across the brand page, the public register and the pack itself. That consistency is one of the strongest trust signals a company can offer when it sells a listed medicine.

9 · References

Australian regulators and public registers

• Therapeutic Goods Administration (TGA) — home
• TGA ARTG — LDV20 (entry 502251)
• TGA — Australian Register of Therapeutic Goods (ARTG)
• TGA — Listed medicines overview
• TGA — Good Manufacturing Practice (GMP)

Ingredient-level and published literature references

• Castaño G, et al. (2001) — Effect of policosanol 20 versus 40 mg/day
• 2017 sugarcane-derived policosanol meta-analysis
• Zhao JV, et al. (2021) — Effect of Berberine on Cardiovascular Disease Risk Factors
• Xia LM, et al. (2016) — Study progress of berberine for treating cardiovascular disease
• NCBI Bookshelf — Milk Thistle (StatPearls, 2024)
• NIH Office of Dietary Supplements — Chromium fact sheet for health professionals

Pure Australia internal pages referenced in this article

• Pure Australia — home
• LDV20 product page
• LDV20 Official Information Center
• LDV20 consumer FAQ
• Pure Australia blog / news index